Skip to main content
Clinical Trials/NCT03446937
NCT03446937
Completed
N/A

Effect of Antenatal Corticosteroids on Neonatal Morbidity.

Ahmadu Bello University Teaching Hospital1 site in 1 country150 target enrollmentDecember 1, 2017

Overview

Phase
N/A
Intervention
Dexamethasone Sodium Phosphate Injection
Conditions
Neonatal Respiratory Distress Syndrome
Sponsor
Ahmadu Bello University Teaching Hospital
Enrollment
150
Locations
1
Primary Endpoint
Neonatal Respiratory distress syndrome
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

It will be a randomized controlled trial. There will be two study groups. Study group 1 will be given dexamethasone while study group 2 will be given betamethasone. The control group will be given placebo.

Detailed Description

The study will be a double blind randomised controlled trial. There will be two study groups and one control group. The first study group will be the pregnant women at risk of late preterm birth that will receive antenatal corticosteroids in the form of intramuscular dexamethasone sodium phosphate. The second study group will be the pregnant women at risk of late preterm birth that will receive antenatal corticosteroids in the form of intramuscular betamethasone sodium phosphate. The control group will be pregnant women at risk of late preterm birth that will be given intramuscular water for injection.

Registry
clinicaltrials.gov
Start Date
December 1, 2017
End Date
May 31, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anisah Yahya

Lecturer I/Fellow

Ahmadu Bello University Teaching Hospital

Eligibility Criteria

Inclusion Criteria

  • Pregnant women at 34 weeks 0 days to 36 weeks 6 days of gestation and a probability of delivery in the late preterm period irrespective of diagnosis who give consent.
  • Pregnant women at 34 weeks 0 days to 36 weeks 6 days of gestation scheduled for elective/emergency delivery in the late preterm period irrespective of indication and route of delivery who give consent.

Exclusion Criteria

  • Evidence of Chrioamnionitis.
  • Evidence of foetal distress.
  • History of use of antenatal corticosteroids in index pregnancy.
  • Women who do not give consent.

Arms & Interventions

Dexamethasone sodium phosphate injection

Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)

Intervention: Dexamethasone Sodium Phosphate Injection

Betamethasone sodium phosphate injection

Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)

Intervention: Betamethasone Sodium Phosphate Injection (Medication)

Water for injection

Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.

Intervention: Water for injection

Outcomes

Primary Outcomes

Neonatal Respiratory distress syndrome

Time Frame: Within the first 72 hours of life

Tachypnoea with grunting, recession, or nasal flaring with diffuse reticulogranular infiltrate on X-ray and oxygen requirement.

Secondary Outcomes

  • Transient tachypnoea of the newborn:(Within the first 72 hours after delivery/birth)
  • Admission into neonatal intensive care unit.(Within the first 72 hours after delivery/birth)
  • 2. Admission into neonatal intensive care unit. Apnoea.(Within the first 72 hours after delivery/birth)

Study Sites (1)

Loading locations...

Similar Trials